(Reuters) - Russia's granting of regulatory approval to a COVID-19 vaccine after less than two months of human testing has prompted expressions of caution as well as interest from around the world.
Moscow said on Wednesday that the first batch of the vaccine would be ready for some medics within two weeks and rejected safety concerns as "groundless".
Already a subscriber? Log in
5.5 PAYDAY OFFER: 35% OFF Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
